Lipid-168
Version 1.eb19ab10 · 2026-09-13
| CAS No. | Not available |
| Chemical Name | Lipid-168 |
| Synonyms | Lipid 168， Lipid168 |
| SMILES | CCCCCCCCCNC(=O)C(CCCCCCCCC(=O)OCC(CCCC)CCCCCC)N(CCCN(CC)CC)C(=O)CCCCCCCC(=O)OCC(CCCC)CCCCCC |
| Formula | C60H117O6N3 |
| M.Wt | 975.89 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery-Saijuan Xu, Dan Liang etl. Nature Biomedical Engineering (2025) |
LIPID168(pKa ~6.5) is an optimized ionizable lipid engineered for in vivo mRNA delivery to hematopoietic stem cells (HSCs) in bone marrow. Developed by Yoltech Therapeutics through high-throughput screening of lipid libraries, it features a diethylamino head group and a tailored hydrophobic tail structure that enables antibody-free targeting. When Lipid 168 was formulated into lipid nanoparticles (LNPs), it achieved 48.5% base editing efficiency in bone marrow cells —surpassing benchmarks like LIPID-028 (19.7%)—and reduced off-target liver editing from 71% to 19% by incorporating miR-122 target sequences. In humanized β-thalassemia models, LNP 168 delivered ABE8e mRNA/sgRNA to patient-derived HSCs, yielding 42.6% editing at the HBG promoter, reactivating fetal hemoglobin (γ-globin) and rescuing erythroid defects . Its bone marrow specificity is driven by a unique protein corona enriched in albumin, fibronectin, and fibrinogen . Safety studies confirmed transient immune responses and no cumulative toxicity . LIPID-168 represents a promising non-viral platform for curative gene therapies in blood disorders.
Specifications shown are product-page values, not batch test results.
Read Instructions for Use →